[EMAIL PROTECTED] writes:
Hi Sue,
The National Cancer Institute was deeply involved in the disreputable story
put out by the "New York Times." There is absolutely nothing original about
the drug being touted, which does not even exist in a form that humans could
take and has not yet even started the paperwork for possible human studies,
while other drugs that are trying the same solution are in Phase I clinical
trials - buried at the bottom of this very story.
I will post a complaint from a Nobel laureate who complains he was misused
and misquoted by the "New York Times" to tout this drug.
>Sue Hartigan <[EMAIL PROTECTED]> writes:
>
>
>Hi Terry:
>
>I found the National Cancer Research page, and here is what they said,
>hope that it helps:
>
> National Cancer
> Institute
>
> May 4, 1998
>
> FOR RESPONSE
> TO INQUIRIES
> NCI Press Office
> (301) 496-6641
> Backgrounder
>
>
> NCI Statement on Animal Studies of
> Endostatin and Angiostatin
>
> The National Cancer Institute (NCI) is
> encouraged by results from animal studies that
> suggest that compounds isolated by researchers
> in the laboratory of Judah Folkman, M.D., of
> Children's Hospital and Harvard Medical School
> in Boston, Mass., may be potent anti-cancer
> agents. NCI has made it a high priority to move
> research forward on these compounds,
> endostatin and angiostatin, so that clinical trials in
> humans can begin. It is important to note that
> such human studies will not begin for many
> months, most likely not until 1999. Once testing
> has begun, the compounds, which are
> anti-angiogenesis agents, must be tested
> separately for safety and efficacy in humans
> before they can be tested together.
>
> Production of these compounds is one part of
> the process that must take place over the next
> several months. At this time, it is not possible to
> produce the large quantities of endostatin or
> angiostatin necessary for human trials. NCI is
> working with Entremed, Inc., on production
> issues for endostatin and with Bristol-Myers
> Squibb Co., on production issues for angiostatin.
>
> It is very important to emphasize that while the
> possibilities raised by these studies in mice are
> encouragaing, it is not known whether endostatin
> or angiostatin will be effective in people with
> cancer.
>
> Clinical trials of other anti-angiogenesis agents
> are under way both by individual drug
> companies and by NCI. Patients interested in
> information about ongoing trials listed in NCI's
> PDQ database can contact the NCI's Cancer
> Information Service at 1-800-4-CANCER or
> search PDQ themselves via the Internet
> (http://cancertrials.nci.nih.gov -- under "more"
> choose Introduction, then choose "finding
> specific trials").
>--
>Two rules in life:
>
>1. Don't tell people everything you know.
>2.
>
>Subscribe/Unsubscribe, email: [EMAIL PROTECTED]
>In the body of the message enter: subscribe/unsubscribe law-issues
>
>
Best, Terry
"Lawyer - one trained to circumvent the law" - The Devil's Dictionary
Subscribe/Unsubscribe, email: [EMAIL PROTECTED]
In the body of the message enter: subscribe/unsubscribe law-issues
